US 6,884,431 B1Granted

Method for treating proliferative diseases with p27 and fusions thereof

AssigneeThe Regents of the University of Michigan

InventorsGary J. Nabel, Elizabeth G. Nabel

Life of this patent

Estimating the term…

Abstract

The present invention is directed to a method of vascular proliferative disease by administering in vivo a gene encoding p27.

Claims13

Dependent claims

A combination for treating a vascular proliferative disease in a patient comprising a nucleic acid encoding a single cyclin-dependent kinase inhibitor contained in a balloon catheter, wherein the cyclin-dependent kinase inhibitor is p27.

Dependencies are inferred from the claim text.

Facts

Application: 09/708,276Filed 7 Nov 2000 · continuation
Priority: 21 Jul 1997
Granted: 26 Apr 2005
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

C12N 9/1211
Phosphotransferases with an alcohol group as acceptor , e.g. protein kinases: thymidine kinase
A61K 38/1709
From vertebrates: from mammals
A61P 9/10
Drugs for disorders of the cardiovascular system: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary…
C07K 14/4703
Regulators; Modulating activity: inhibitors; Suppressors

Family

Application08/897,333Parent of this continuation · filed 21 Jul 1997
US 6,177,272 B1Parent of this continuation
US 6,884,431 B1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results